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Many organic molecules form colloidal aggregates in aqueous solution at micromolar concentrations.
Theseaggregatespromiscuouslyinhibitsolubleproteinsandareamajorsourceoffalsepositivesinhigh-
throughput screening. Several drugs also form colloidal aggregates, andthere has been speculation that
thismayaffecttheabsorptionanddistributionofatleastonedruginvivo.Hereweinvestigatetheability
of drugs to form aggregates in simulated intestinal fluid. Thirty-three Biopharmaceutics Classification
System (BCS) class II and class IV drugs, spanning multiple pharmacological activities, were tested for
promiscuous aggregation in biochemical buffers. The 22 that behaved as aggregators were then tested
for colloid formation in simulated intestinal fluid, a buffer mimicking conditions in the small intestine.
Six formed colloids at concentrations equal to or lower than the concentrations reached in the gut,
suggesting that aggregation may have an effect on the absorption and distribution of these drugs, and
potentially others, in vivo.
Early drug discovery suffers from a high rate of false posi-
tives. This problem is particularly acute in high-throughput
screening.
1-5Manyofthesefalsepositive“hits”areattributed
to promiscuously inhibiting colloidal aggregates, which are
spontaneouslyformedbymanyorganicmoleculesinaqueous
solution.
6-9 Once formed, these aggregates nonspecifically
inhibit protein by sequestration and partial denaturation.
2,10
Originallyconsideredaproblemofscreening,itbecameappa-
rent that most classes of bioactive organic small molecules
could form colloidal aggregates at micromolar concentra-
tions. In succession, it was shown that probe molecules such
as kinase inhibitors,
11-13 natural products such as quercetin
2
and adociasulfate-2,
9 and even drugs such as nicardipine,
delavirdine, clotrimazole, and cinnarizine
14,15 could form col-
loids.Asdisconcertingasitwastofindaggregatingdrugs,this
was thought to be a problem relevant only for screening con-
ditions in biochemical buffers and not for in vivo effects.
Subsequently, however, Arnold, Janssen, and colleagues
argued that aggregation may indeed affect the distribution
of oral drugs in vivo.
16-18 After observation that some
hydrophobic non-nucleoside reverse transcriptase inhibitors
(NNRTIs
a) showed surprisingly high bioavailability in vivo,
their pharmacokinetic and physiochemical properties were
investigated.
16-18 Many compounds from the diaryltriazine/
diarylpyrimidineclassesofNNRTIswereshowntoaggregate
in gastric-mimicking conditions, with a distinct particle size
difference between highly and poorly absorbed compounds
(radii from 30 to 100 nm and >250 nm, respectively).
16,18
A model of aggregate absorption into the lymphatic pathway
viamicrovilli(M)cellsinPeyer’spatchesinthesmallintestine
was proposed. To test this hypothesis in vivo, the diarylpyri-
midine dapivirine was administered orally to dogs, and drug
concentrationsinthelymphfluidandplasmawerecompared;
at 2 h, the lymph concentration was 3 times that of plasma,
consistent with primary absorption via the lymphatic system,
perhaps as colloidal aggregates.
18 In response to these find-
ings, experiments were conducted to show that colloidal aggre-
gates are unperturbed by high concentrations of protein as
found in biological environments, supporting the idea that
stable colloid formation may be possible in vivo.
19
Two questions emerge from these observations. First, how
manydrugsaggregateinconditionsencounteredintheGItract?
Second, how would such aggregation affect their absorption
anddistribution?Thesecondquestionischallengingtoaddress,
but as a preliminary step, it seemed useful to investigate the
abilityofabroadrangeoforaldrugs,mostlyBCSclassIIand
class IV low solubility drugs, to aggregate in a buffer simulat-
ing the conditions of the small intestine. Thirty-three mar-
ketedoraldrugs,coveringmanybiologicalactivities,werefirst
tested for aggregation in biochemical buffers by measuring
particle formation and aggregation-based inhibition. Those
that formed colloids were then tested for aggregation in fed
state simulated intestinal fluid (FeSSIF). Drugs were assayed
for particle formation up to concentrations that would be
found in the gut following oral administration. To test whether
the particles detected by light scattering share the same pro-
perties as previously characterized colloidal aggregates,
2,14,15
sedimentation assays were conducted and aggregates were
visualized by transmission electron microscopy. We consider
the implications of these observations and the further studies
on actual in vivo distribution that they suggest.
Results
Thirty-three diverse oral drugs were tested for colloid
formation in biochemical buffers (Figure 1). We chose low
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solubilitydrugswithhighClogPvalues,astheyaremoreprone
to aggregation than high solubility drugs.
15 We also tested
methylene blue, a dye used in several clinical indications and
nowinclinicaltrialsfortreatmentofAlzheimer’sdisease.
20-22
Twocriteriawereusedtocharacterizecolloid-formingdrugs:par-
ticle formation and detergent-reversible enzyme inhibition.
7,23-25
Drugsweretesteduptoconcentrationsthatwouldbefoundin
thesmallintestineafteroraladministration.Theseconcentra-
tionswerecalculatedusingmaximumdosageinformationand
assuming a small intestine volume of 1 L.
26-28 We note that
this volume is amongthe higher estimates, withrecentstudies
reportingvolumes closerto300 mL or evenlower.
29-32Thus,
we believe these concentrations to be conservative to the low
side. Particle radii were measured by dynamic light scattering
(DLS), and IC50 values were measured against cruzain in the
presence and absence of Triton X-100. The cruzain inhibition
assay was used instead of the classical aggregation-based
AmpC β-lactamase inhibition assay because the fluorogenic
reporting system allows for a more efficient high-throughput
setup. Several compounds were limited by solubility in the
cruzain assay; in these cases, inhibition never reached 50%,
and the IC50 values were reported as greater than the highest
soluble concentration tested. Of the 33 drugs assayed, 22 drugs
formed colloids in biochemical buffers (Table 1, Figure 1).
Drugs classified as noncolloid formers did not meet one or
both criteria for colloid formation.
Toinvestigatewhethercolloid-formingdrugscanalsoform
aggregatesunder in vivo-like conditions, wetestedthe22 drugs
Figure 1. Chemical structures of drugs tested for aggregation in biochemical buffers.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 4261
infedstatesimulatedintestinalfluid(FeSSIF),abufferwidely
used for drug dissolution studies.
27,33-35 FeSSIF is designed
to mimic the conditions in the small intestine following meal
ingestion. This biorelevant medium differs from the buffer
used by Frenkel et al. to investigate aggregate formation by
NNRTIs.Whereastheirgroupsimulatedgastricconditions,
16
we simulated intestinal conditions to more closely resemble
theenvironmentofpotentialaggregateabsorptionviaPeyer’s
patches located in the small intestine.
27,28 Particle formation
in FeSSIF was measured by DLS. Six drugs (18% of total
drugs included in this study, 27% of colloid formers in
biochemical buffers) formed particles in FeSSIF at concen-
trations substantially lower than would be present in the gut
following oral administration (Table 2). Because of the high
content of taurocholate, FeSSIF contained micelles that add
to the light scattering measured by DLS. To verify that
colloidalparticlesweredistinguishablefromthisbackground,
standardcalibrationbeads(r=200nm)weredilutedinFeSSIF
and light scattering was measured. As seen in Figure 2C, the
bead-containing samples exhibited strong autocorrelation
curvesofaclearlydifferentshapethanFeSSIFwithoutbeads.
ThesixdrugsthataggregatedinFeSSIFshowedstrongcurves
similartothebead-containingsamplesanddistinctfromFeSSIF
background, consistent with the presence of colloidal aggre-
gates (Figure 2B).
To ensure that the large particles observed by DLS were
indeedcolloidalaggregates,theirpropertieswerecomparedto
previously characterized aggregates. A distinguishing charac-
teristic of colloidal aggregates is their critical aggregation
concentration (CAC) at which colloids will form; compound
below that CAC will remain in true solution in monomeric
form. Upon centrifugation,the colloids willbe pelleted out of
solution while the monomeric molecules will remain in the
supernatant.
2,14 Samples of itraconazole (35 μM, 0.35%
DMSO) and delavirdine (750 μM, 3% DMSO) in FeSSIF
were centrifuged; their CAC values are 6.9 ( 1.9 and 488.3 (
31.0 μM, respectively. Consistent with the formation of
colloidal aggregates, these drugs were pelleted out of solution
in FeSSIF in a CAC-dependent manner as demonstrated by
the percent of each drug collected in the pellet (Figure 3).
Additionally, colloid formers have been shown to interact
directlywithproteininbiochemicalbuffers.
2,10Toinvestigate
whether or not this interaction also occurs in FeSSIF, we
analyzed β-lactamase cosedimentation with colloid forming
drugs. Itraconazole and delavirdine were incubated with 2 μg
ofβ-lactamaseinFeSSIFandcentrifugedtopelletcolloidsout
of solution. If β-lactamase binds to the colloid surface,
the protein will be pelleted with the drug, whereas unbound
protein will remain in the supernatant. The large amount
of protein in drug-containing pellets (lanes 6 and 9) versus
β-lactamase alone (lane 3) indicates that colloids do bind
protein in FeSSIF (Figure 4). Pellets of drug samples without
proteinwereincludedintheSDS-PAGEgel(lanes4and7)to
ensure that drug alone did not cause background in the silver
staining.
If drugs form colloids in FeSSIF, they should be visible by
transmission electron microscopy and distinguishable from
precipitate,whichwouldappearmicrocrystallineinstructure.
We compared aggregates of itraconazole, delavirdine mesy-
late, and methylene blue in phosphate buffer to those formed
inFeSSIF(Figure5).Thoughtherearestrongbackgroundsof
phospholipid structures in the FeSSIF samples, the colloidal
aggregates are readily visible over this background. By shape
andgeneralappearance,theparticlesinFeSSIFresembletheir
counterparts in phosphate buffer, as well as previously pub-
lished micrographsofaggregating compounds,
2,16-18and are
clearly not in a precipitated form. The colloids formed in
FeSSIF are visibly smaller than those formed in phosphate
buffer,complementingtheresultsobtainedbylightscattering.
Discussion
Oral drugs have stringent solubility and permeability con-
straints,
36 and so it may seem baffling that so many form col-
loidalaggregatesinsimplebuffersorthatanydosoinsimulated
intestinal fluid. Nevertheless, those are the central observa-
tions of this study. Of the 33 drugs tested, 22 aggregated at
relevant concentrations in phosphate buffer (67%) and 6 did
so in FeSSIF (18% of total drugs tested; 27% of colloid
formers). Admittedly, these oral drugs were chosen for their
low solubility BCS classifications; thus, we were examining a
biased set. Also, the earlier work by Arnold, Janssen, and
colleagues on the diarylpyrimidine NNRTIs
16-18 and our own
studies on drug aggregation
15 suggested that it was at least
plausible that some drugs would behave this way. That so
many did so, across pharmacological classes, surprised us.
Since aggregation is concentration and condition dependent,
this behavior and its implications merit close scrutiny.
Many of the drugs studied here, like imatinib, celecoxib,
amiodarone, and meclizine, are household names and have
been taken by hundreds of millions of people. In phosphate
bufferthereis littledoubt thatthey formcolloidalaggregates.
They scatter light intensely by DLS, with well-formed autocor-
relationcurvesconsistent withparticlesizes inthe100-500 nm
Table 1. Colloid Formation in Biochemical Buffers
IC50 vs cruzain
a (μM)
drug
no Triton
X-100
0.01%
Triton
X-100
DLS concn
b
(μM)
colloid radius (
SD (nm)
amiodarone 4 206
c 2 64.0 ( 12.0
candesartan
cilexetil
42 168
c 50
d 38.8 ( 10.1
celecoxib 126 >400 120
e 161.8 ( 14.0
chlorpromazine 189 284 500 29.2 ( 0.8
cinnarizine
f 124 >300
c 10 89.1 ( 10.6
clofazimine 6 40 10 356.1 ( 18.9
clopidogrel
sulfate
123 >300 60
g 48.3 ( 2.0
delavirdine
f 122 >200 100
h 195.1 ( 22.5
etravirine
f 4 >200 10 323.2 ( 14.1
fenofibrate 61 >500 10 129.0 ( 6.8
gefitinib 88 148 250
h 160.1 ( 11.4
imatinib 207 297 100 118.4 ( 19.2
itraconazole 3 >200 2.5 138.1 ( 8.3
manidipine 6 >100 2.5 125.6 ( 7.3
meclizine 129 >250 5 133.3 ( 7.5
menatetrenone 18 >200 5 72.5 ( 6.1
methylene blue 55 85 20 95.9 ( 12.5
nelfinavir 144 >300 20 690.7 ( 217.2
pranlukast 7 68
c 50 1167.7 ( 293.8
raloxifene 33 128
c 20 192.2 ( 20.2
(()-R-tocopherol
nicotinate
98 >400 10 104.1 ( 3.3
triclabendazole 15 >200 10 93.0 ( 5.1
a95%confidenceintervalsarelistedinSupportingInformationTable1.
bIndicates the drug concentration at which DLS measurements were
made. 1% DMSO was used unless otherwise noted.
c0.1% Triton X-100.
d0.25% DMSO.
e0.6% DMSO.
fPreviously published aggregator.
g0.3% DMSO.
h0.5% DMSO.4262 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 Doak et al.
size range (Figure 2A), as has been observed previously for
other classes of molecules. They inhibit the reporter enzyme
cruzain
24 at low to mid-micromolar concentrations, and this
inhibitioncanbereversedwithlowconcentrationsofthenon-
ionic detergent Triton X-100 (Table 1). This has two implica-
tions.First,panelsofdrugsareoftenfirstchoiceswhenscreening
against a new target because they are expected to have good
physiochemical properties and because they are information-
rich molecules. Whereas this logic remains sound, a lesson
from this study is that they offer no panacea; drugs and other
biomolecules
24canformcolloidalaggregatesunderscreening-
relevantconditions,andwhentheydoso,theyareproneto
Table 2. Colloid Formation in Simulated Intestinal Fluid
a
aDLS measurements were made using 1% DMSO unless otherwise noted.
bCalculated using maximum drug dosage and 1 L volume in small
intestine.
26-28 c3% DMSO.
d0.2% DMSO.
e0.75% DMSO.
Figure 2. Autocorrelation curves from DLS showing (A) drugs in 50 mM phosphate buffer and (B) in FeSSIF: (b) KPi, (1) tocopherol nico-
tinate, ([) etravirine, (2) delavirdine, (9) menatetrenone, (3) itraconazole, (4) methylene blue. (C) Calibration beads in FeSSIF: (b) FeSSIF,
(1) 15 fM beads, ([) 60 fM beads, (2) 240 fM beads, (9) 480 fM beads. Each curve is one representative sample from each set.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 4263
induce screening artifacts. Second, aggregation in the intes-
tine may be more common even than what we describe here.
We have used conservative estimates for the maximum con-
centration reached by drugs in the intestine, assuming a 1 L
volumefor this compartment.Had wechosen lower volumes,
as recently reported,
29-32 the maximum concentration would
have been higher and so their likelihood of aggregating. For
instance,drugslikecandesartan,clofazimine,andfenofibrate,
whichdonotaggregateinFeSSIFatthelowerconcentrations
usedhere,begintodosoathigherconcentrations(Supporting
Information Table 2, Supporting Information Figure 1).
Colloid formation in simulated intestinal fluid is harder to
assay, largely because of the presence of the detergent-like
taurocholate, and since this is the most interesting conclusion
of this study we will reprise the observations that support it.
Whereas the FeSSIF adds to background light scattering, the
DLS curves for the six aggregating drugs in that medium
remain clear: the autocorrelation curves are well formed and
distinctive from FeSSIF background (Figure 2B). Intrigu-
ingly,theradiioftheparticlesarediminishedinFeSSIFversus
phosphate, consistent with the FeSSIF affecting their char-
acter and moving them into a size range where they might be
betterabsorbedbyparticle-detectingcellsofthePeyer’spatch,
as first suggested by Arnold, Janssen, and colleagues.
16 As
with well-studied, “classical” colloid formers, such as tetra-
iodophenolphthalein and nicardipine, drugs like itraconazole
anddelavirdinemaybepelletedoutofFeSSIFbycentrifugation
when they reach concentrations above their CAC, whereas
they cannot be pelleted out when below their CAC values.
Additionally, these pelleted colloids can pull protein down
with them, which indicates a direct colloid-protein interac-
tion, as previously demonstrated.
2 Finally, drugs like itraco-
nazole, delavirdine, and methylene blue form distinct sphe-
roid particles, in the 100 nm size range, by negative staining
transmission electron microscopy. Although these particles
must be disentangled from a background of lipid/detergent
structures in FeSSIF, this may be done without strain, as the
lecithin and taurocholate form thin layers of lipid/detergent
structures while the drug colloids stand out by their dimen-
sionality, shape, and size. Taken together, these observations
leave little room for doubt that 6 of the 33drugs studied here,
delavirdine, etravirine, itraconazole, menatetrenone, methy-
leneblue,andtocopherol,formcolloidalaggregatesinamedium
widely accepted to mimic the fed state of the small intestine.
Certain caveats, codicils, and conditions merit airing. We
have shown that six drugs form colloids in FeSSIF at con-
centrations likely to be reached at or below their highest
administered dose, taking a conservative (high) estimate of
fed-statesmallintestinevolume,andanotherthreedrugsdoso
at higher concentrations. Still, it remains true that many do
not form colloids in FeSSIF, even from the biased group of
oral drugs from which the 33 were drawn. We do not argue
that this effect applies to most drugs or even, at least at this
stage, very many. Our results do not, at this point, suggest
even a physical SAR around which drugs might aggregate in
FeSSIF.WhereaslowsolubilityBCSclassIIandclassIVoral
drugs,fromwhichmostofthosetestedhereweredrawn,seem
morelikelytoaggregateundertheseconditions,thosethatdid
Figure 3. UV-visible quantification of colloids pelleted from FeS-
SIF by centrifugation. Bars illustrate the percent found in the (0)
supernatant and (9) pellet: (a) nicardipine (60 μM), a previously des-
cribed strong aggregator, in 50 mM KPi; (b) nicardipine (60 μM),
which is not observed to form colloids in FeSSIF; (c) itraconazole
(35 μM); (d) delavirdine mesylate (750 μM).
Figure 4. β-Lactamase cosediments with colloids in FeSSIF. Lane
1i s2μgo fβ-lactamase in 1 mL of FeSSIF, without centrifugation.
Lanes 2 and 3 are the supernatant (S) and pellet (P), respectively,
from centrifugation of β-lactamase alone. Lanes 4 and 7 are the pellets
from centrifugation of each colloid-forming drug alone. Lanes 5 and
8 are the supernatants, and lanes 6 and 9 are the pellets of β-lactamase
incubated with colloid forming drugs.
Figure 5. Negative stain electron microscopy of colloid-forming
compounds. (A) Phosphate buffer is shown with homogeneous
background without particulates. (B) Itraconazole in phosphate
buffer forms large colloids, while under the same conditions methy-
lene blue (C) and delavirdine mesylate (D) form small and inter-
mediate sized colloids, respectively. (E) Negatively stained FeSSIF
revealsonlylow-contrastlipidanddetergentstructuresbasedonthe
taurocholate and lecithin content. Itraconazole (F), methylene blue
(G),anddelavirdinemesylate(H)retaintheircolloidformingability
in FeSSIF, forming colloids similar to those seen in phosphate
buffer. The contrast for panels B, C, D, G, and H was adjusted
nonlinearlybyusingahigh-passFourierfiltertoreducetheintensity
of the negative stain. Bar = 100 nm.4264 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 Doak et al.
soinFeSSIFspanawiderangeofClogPvaluesandmolecular
weights, with both the most lipophilic (menatetrenone and
tocopherol)andthemosthydrophilic(delavirdineandmethy-
lene blue) and several in the midrange forming colloids, while
physically related compounds do not. Nor do we pretend,
even for the six drugs that do aggregate in FeSSIF, that this
means they do so in the intestine; far less have we shown that
they are absorbed as colloidal particles into systemic, lym-
phatic circulation. Doing so will demand more detailed,
physiologically relevant studies in animals. What this study
does sustain is the reasonability of this hypothesis, first aired
by others,
16,18 for some oral drugs. Certainly the observation
that these six drugs form colloidal aggregates in simulated
intestinal fluid is strongly supported by multiple lines of evi-
dence. Ifdrugsdoform colloidsinthe small intestine, itcould
affect their absorption and distribution, either by delaying
these processes or by changing distribution sites and time
courses.Itgoeswithoutsayingthatthesearecriticalaspectsof
drugpharmacokineticsandefficacy.Akeyresultofthisstudy
is that the drug aggregation in the small intestine remains a
reasonablehypothesis,anditseffectsondrugbehaviorwould
beso fundamental astomeritfurther study in physiologically
relevant systems.
Materials and Methods
Materials. Cruzain was expressed and purified as previously
described.
37 Duke Standards NIST traceable polymer micro-
spheres, 200 nm in diameter, were purchased from Thermo
Scientific.Amiodaronehydrochloride,cinnarizine,clofazimine,
fenofibrate, menatetrenone, methylene blue, nicardipine hydro-
chloride, (()-R-tocopherol nicotinate, triclabendazole, chlor-
promazine hydrochloride, hydroxyzine dihydrochloride, nicer-
goline, taurocholic acid sodium salt hydrate, and L-R-lecithin
(fromeggyolk)werepurchasedfromSigma-Aldrich.Celecoxib,
clopidogrel sulfate, imatinib, itraconazole, manidipine, cande-
sartan cilexetil, eprosartan mesylate, irbesartan, loratadine, lova-
statin, telmisartan, and valsartan were purchased from AK
Scientific. Pranlukast, raloxifene hydrochloride, and simvasta-
tin were purchased from US Biological. Delavirdine mesylate
was purchased from BIOMOL International, meclizine dihydro-
chloride from MP Miomedicals, cilostazol from Bosche Scien-
tific, LLC, gefitinib from LC Laboratories, iopanoic acid from
TCIAmerican,andnelfinavirfromRyanScientific. Mostofthe
drugs chosen for this study were BCS class II and class IV drugs
with ClogP values greater than 3.5.
FeSSIF Preparation. Blank FeSSIF was prepared by adding
8.65 g of acetic acid and 15.2 g of potassium chloride to deioni-
zed water. Sodium hydroxide was added until pH 5.0 was rea-
ched. Full media were prepared fresh each day. Blank FeSSIF
was filtered through a 0.22 μm filter, and sodium taurocholate
and lecithin were added to 15 and 3.75 mM, respectively, and
dissolved by heating to 37 C and vortexing.
Dynamic Light Scattering. Concentrated DMSO stocks of
drugs were diluted with filtered 50 mM KPi, pH 7.0, or FeSSIF.
The finalDMSOconcentration was 1%unless otherwisenoted.
MeasurementsweremadeusingaDynaProMS/X(WyattTech-
nology) with a 55 mW laser at 826.6 nm. The laser power was
100%, and the detector angle was 90. Each diameter value
reported represents the average of three or more independent
measurements at room temperature. The compositions of sam-
ples in phosphate buffer in Figure 2 are 10 μM tocopherol nico-
tinate, 1% DMSO; 10 μM etravirine, 1% DMSO, 100 μM
delavirdine,0.5%DMSO,1μMmenatetrenone,0.01%DMSO,
1 μM itraconazole, 0.04% DMSO, and 30 μM methylene blue,
0.06% DMSO; and in FeSSIF are 100 μM tocopherol nicoti-
nate, 0.4% DMSO, 150 μM etravirine, 0.6% DMSO, 600 μM
delavirdine,3%DMSO,5μMmenatetrenone,1%DMSO,20μM
itraconazole, 0.2% DMSO, and 200 μM methylene blue, 2%
DMSO. Figure 5 shows results from 600 μM clofazimine, 6%
DMSO;550μMcandesartancilexetil,2.75%DMSO;and450μM
fenofibrate, 1.8% DMSO.
Cruzain Assay. Cruzain assays were performed in 100 mM
sodium acetate, pH 5.5, containing 5 mM DTT. Triton X-100
was added to 0.01% or 0.1% in reaction mixtures as needed.
Drugs were incubated with 0.8 nM cruzain for 5 min until reac-
tions were initiated by adding the fluorogenic substrate Z-Phe-
Arg-aminomethylcoumarin (Z-FR-AMC). The final reaction
volume was 200 μL with cruzain at 0.4 nM and ZF-R-AMC at
2.5 μM. Final DMSO concentrations were generally 0.5% and
nogreater than5%,dependingonthe rangeof thedrugconcen-
trationinvestigated.Tomeasureenzymeinhibition,theincrease
in fluorescence (excitation wavelength of 355 nm, emission wave-
length of 460 nm) was recorded for 5 min in a microtiter plate
spectrofluorimeter (Molecular Devices, FlexStation). Assays
were performed in duplicate in 96-well plates, with controls
measuring enzyme activity in the presence of DMSO. Activity
wasmeasuredforatleastsevendifferentconcentrationsforeach
drug. Dose-response curves were plotted, and IC50 values and
corresponding 95% confidence intervals were calculated using
GraphPadPrism4(GraphPad,SanDiego,CA),usingasigmoi-
dal dose-response curve analysis with variable slope and the
bottom constrained to be greater than zero.
Sedimentation Assay. Solutions of nicardipine (60 μM, 1%
DMSO), itraconazole (35 μM, 0.35% DMSO), and delavirdine
mesylate (750 μM, 3% DMSO) were prepared by diluting con-
centrated DMSO stocks into 50 mM KPi, pH 7.0, or FeSSIF,
withafinalvolumeof1mL.Sampleswerecentrifugedat16000g
for 1 h at room temperature. Delavirdine mesylate was centri-
fuged at 76000g for 1 h. Supernatants were removed and pellets
(bottom10μL) wereresuspendedto1mLwithDMSOormethanol.
UV-visible spectrophotometry was used to determine the con-
centrationofcompoundinthesupernatantandtheresuspended
pellet. Absorbance was measured at 352 nm for the nicardipine
supernatant in phosphate buffer (ε = 4.6  10
3 M
-1 cm
-1),
355 nm for the FeSSIF supernatant (ε=6.7  10
3 M
-1 cm
-1),
and355nmforbothpelletsinDMSO(ε=6.410
3M
-1cm
-1).
Absorbance was measured at 264 nm for the itraconazole
supernatant (ε=21.9  10
3 M
-1 cm
-1) and at 267 nm for the
pellet in DMSO (ε = 25.9  10
3 M
-1 cm
-1). Absorbance was
measured at 301 nm for the delavirdine supernatant (ε=19.4 
10
3M
-1cm
-1) and pellet in methanol (ε=24.310
3M
-1cm
-1).
BarsinFigure3representthemeanandstandarddeviationofat
least three replicate measurements.
Cosedimentation Assay. Solutions of itraconazole (200 μM,
2% DMSO) and delavirdine mesylate (700 μM, 3% DMSO)
were prepared asabove in FeSSIF, with additional samples also
including2μgofAmpC.Sampleswerecentrifugedat16000gfor
30 min at room temperature. After removal of all supernatant
liquid,pelletswereresuspendedwith5μLofDMSOplus5μLof
50mMKPi,pH7.0,andrunonanSDS-PAGEgel.Proteinwas
detected using silver staining.
Negative Staining and Transmission Electron Microscopy.
SolutionswerepreparedbydilutingconcentratedDMSOstocks
of drugs with FeSSIF. The negative staining was performed as
previously described.
38 In brief, negative staining was done on
formvar/carbon coated 200 mesh copper grids (Ted Pella, Inc.;
Redding, CA) which were glow discharged prior to staining.
Then 5 μL samples were adsorbed for ∼30 s and the grids were
stained with 2 drops (50 μL) of freshly filtered 2% ammonium
molybdate. After drying, the samples were viewed in a FEI
Tecnai F20 electron microscope (Eindhoven, The Netherlands)
at 80 kV and a standard magnification of 25000. Electron
micrographs were recorded with a Gatan Ultrascan CCD camera.
The magnification was calibrated using negatively stained cat-
alase crystals and ferritin. Figure 5 shows 50 μM itraconazole,
0.5% DMSO, 100 μM methylene blue, 0.2% DMSO, and 200 μM
delavirdine mesylate, 0.2% DMSO in 50 mM phosphate; andArticle Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 4265
100 μM itraconazole, 1% DMSO, 200 μM methylene blue, 1%
DMSO; and 700 μM delavirdine mesylate, 3% DMSO in FeSSIF.
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